Serum sphingosine-1-phosphate levels are associated with brain metastasis in EGFR-mutant lung adenocarcinoma.

IF 2.6 4区医学 Q2 ONCOLOGY

Future oncology Pub Date : 2025-09-01 Epub Date: 2025-07-31 DOI:10.1080/14796694.2025.2539059

Gang Xu, Yajie Li, Bo An, Bo Pan, Lihua Shang, Yan Yu, Dexin Jia

{"title":"Serum sphingosine-1-phosphate levels are associated with brain metastasis in EGFR-mutant lung adenocarcinoma.","authors":"Gang Xu, Yajie Li, Bo An, Bo Pan, Lihua Shang, Yan Yu, Dexin Jia","doi":"10.1080/14796694.2025.2539059","DOIUrl":null,"url":null,"abstract":"Aim: To investigate the association between serum sphingosine-1-phosphate (S1P) levels and brain metastasis in EGFR-mutant lung adenocarcinoma (LUAD).Methods: Serum S1P levels were analyzed in 103 LUAD patients. The baseline characteristics of the 103 patients in this study included the following: the overall cohort consisted of 50.49% males and 49.51% females. The average age of the cohort was 69.50 years (SD = 59.12). Regarding EGFR mutations, 52 patients (50.49%) had wild-type EGFR, 19 patients (18.45%) had EGFR Ex19Del, and 32 patients (31.07%) had the L858R mutation. Logistic regression models and competing risk Cox analyses were used to evaluate the association between S1P levels and brain metastasis. Kaplan-Meier curves assessed cumulative brain metastasis incidence over time.Results: Serum sphingosine-1-phosphate (SIP) levels were measured with the following results (mean ± SD): wild-type EGFR, 970.44 ± 344.37 nmol/L; Ex19Del, 1,246.41 ± 306.93 nmol/L; and L858R, 1,333.21 ± 385.08 nmol/L (p < 0.001). In EGFR-mutant patients, S1P levels were independently associated with increased risk of brain metastasis (OR = 8.2, p = 0.003; HR = 105, p < 0.001), whereas no significant association was observed in EGFR wild-type patients. Kaplan-Meier analysis revealed that high S1P levels were linked to earlier brain metastasis in EGFR-mutant patients (p = 0.0034). The relationship between S1P levels and brain metastasis was not significantly influenced by the presence of bone metastasis (p > 0.1).Conclusion: Elevated serum S1P levels are significantly associated with brain metastasis in EGFR-mutant LUAD patients. S1P may serve as a biomarker for brain metastasis risk and a potential therapeutic target.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2757-2765"},"PeriodicalIF":2.6000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12408039/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14796694.2025.2539059","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/31 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: To investigate the association between serum sphingosine-1-phosphate (S1P) levels and brain metastasis in EGFR-mutant lung adenocarcinoma (LUAD).

Methods: Serum S1P levels were analyzed in 103 LUAD patients. The baseline characteristics of the 103 patients in this study included the following: the overall cohort consisted of 50.49% males and 49.51% females. The average age of the cohort was 69.50 years (SD = 59.12). Regarding EGFR mutations, 52 patients (50.49%) had wild-type EGFR, 19 patients (18.45%) had EGFR Ex19Del, and 32 patients (31.07%) had the L858R mutation. Logistic regression models and competing risk Cox analyses were used to evaluate the association between S1P levels and brain metastasis. Kaplan-Meier curves assessed cumulative brain metastasis incidence over time.

Results: Serum sphingosine-1-phosphate (SIP) levels were measured with the following results (mean ± SD): wild-type EGFR, 970.44 ± 344.37 nmol/L; Ex19Del, 1,246.41 ± 306.93 nmol/L; and L858R, 1,333.21 ± 385.08 nmol/L (p < 0.001). In EGFR-mutant patients, S1P levels were independently associated with increased risk of brain metastasis (OR = 8.2, p = 0.003; HR = 105, p < 0.001), whereas no significant association was observed in EGFR wild-type patients. Kaplan-Meier analysis revealed that high S1P levels were linked to earlier brain metastasis in EGFR-mutant patients (p = 0.0034). The relationship between S1P levels and brain metastasis was not significantly influenced by the presence of bone metastasis (p > 0.1).

Conclusion: Elevated serum S1P levels are significantly associated with brain metastasis in EGFR-mutant LUAD patients. S1P may serve as a biomarker for brain metastasis risk and a potential therapeutic target.

查看原文本刊更多论文

血清鞘氨醇-1-磷酸水平与egfr突变型肺腺癌脑转移相关

目的：探讨egfr突变型肺腺癌（LUAD）患者血清鞘氨醇-1-磷酸（S1P）水平与脑转移的关系。方法：分析103例LUAD患者血清S1P水平。本研究103例患者的基线特征包括：整个队列中男性占50.49%，女性占49.51%。队列的平均年龄为69.50岁（SD = 59.12）。EGFR突变中，野生型EGFR 52例（50.49%），Ex19Del EGFR 19例（18.45%），L858R突变32例（31.07%）。采用Logistic回归模型和竞争风险Cox分析来评估S1P水平与脑转移之间的关系。Kaplan-Meier曲线评估随时间累积的脑转移发生率。结果：测定血清鞘氨醇-1-磷酸（SIP）水平，结果如下（mean±SD）：野生型EGFR为970.44±344.37 nmol/L；Ex19Del, 1,246.41±306.93 nmol/L；1333 .21 L858R,±385.08 nmol / L (p p p = 0.0034)。S1P水平与脑转移的关系不受骨转移的影响（p < 0.01）。结论：egfr突变LUAD患者血清S1P水平升高与脑转移密切相关。S1P可能作为脑转移风险的生物标志物和潜在的治疗靶点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Future oncology ONCOLOGY-

CiteScore

5.40

自引率

3.00%

发文量

335

审稿时长

4-8 weeks

期刊介绍： Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community. The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.